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during pregnancy on stillbirths
Madiha Syed, Hasan Javed, Mohammad Yawar Yakoob, Zulfiqar A Bhutta*
Abstract
Background: Diabetes during pregnancy is associated with significant risk of complications to the mother, fetus
and newborn. We reviewed the potential impact of early detection and control of diabetes mellitus during
pregnancy on stillbirths for possible inclusion in the Lives Saved Tool (LiST).
Methods: A systematic literature search up to July 2010 was done to identify all published randomized controlled
trials and observational studies. A standardized data abstraction sheet was employed and data were abstracted by
two independent authors. Meta-analyses were performed with different sub-group analyses. The analyses were
graded according to the CHERG rules using the adapted GRADE criteria and recommendations made after
assessing the overall quality of the studies included in the meta-analyses.
Results: A total of 70 studies were selected for data extraction including fourteen intervention studies and fifty six
observational studies. No randomized controlled trials were identified evaluating early detection of diabetes
mellitus in pregnancy versus standard screening (glucose challenge test between 24th to 28th week of gestation) in
pregnancy. Intensive management of gestational diabetes (including specialized dietary advice, increased
monitoring and tailored dietary therapy) during pregnancy (3 studies: 3791 participants) versus conventional
management (dietary advice and insulin as required) was associated with a non-significant reduction in the risk of
stillbirths (RR 0.20; 95% CI: 0.03-1.10) (‘moderate’ quality evidence). Optimal control of serum blood glucose versus
sub-optimal control was associated with a significant reduction in the risk of perinatal mortality (2 studies, 5286
participants: RR=0.40, 95% CI 0.25- 0.63), but not stillbirths (3 studies, 2469 participants: RR=0.51, 95% CI 0.14-1.88).
Preconception care of diabetes (information about need for optimization of glycemic control before pregnancy,
assessment of diabetes complications, review of dietary habits, intensification of capillary blood glucose self-
monitoring and optimization of insulin therapy) versus none (3 studies: 910 participants) was associated with a
reduction in perinatal mortality (RR=0.29, 95% CI 0.14 -0.60). Using the Delphi process for estimating effect size of
optimal diabetes recognition and management yielded a median effect size of 10% reduction in stillbirths.
Conclusions: Diabetes, especially pre-gestational diabetes with its attendant vascular complications, is a significant
risk factor for stillbirth and perinatal death. Our review highlights the fact that very few studies of adequate quality
are available that can provide estimates of the effect of screening for aid management of diabetes in pregnancy
on stillbirth risk. Using the Delphi process we recommend a conservative 10% reduction in the risk of stillbirths, as
a point estimate for inclusion in the LiST.
Background
With increasing prevalence of diabetes, the prevalence
of diabetes complicated pregnancies is also increasing.
Normally, as the pregnancy progresses, mothers experi-
ence lower glucose levels compared to the non pregnant
state. With the progression of pregnancy there is lowered
glucose tolerance, increasing glucose and insulin levels.
Although this is a normal physiological process, it can
become pathological in 3-6 % pregnancies [1]. Gesta-
tional diabetes is defined as any degree of glucose intoler-
ance with onset or first recognition during pregnancy [2].
A woman can also be diabetic prior to pregnancy and
that falls into two categories: type 1and type 2. Type 1
diabetes occurs due to a lack of pancreatic islet beta cells,
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caused by autoimmune destruction and resulting in an
absence of insulin; while type 2 diabetes occurs due to
insulin resistance and beta cell dysfunction and is likely
to be the result of interactions between genetic, environ-
mental and immunological factors including diet, physi-
cal activity and obesity [3]. Women diagnosed with
diabetes prior to pregnancy (pre-existing diabetes)
will experience an increase in insulin demands during
pregnancy [4].
Diabetes can have significant impacts on maternal, fetal
and neonatal outcomes. The presence of diabetes can
increase the risk of stillbirth by five times, and the risk of
neonatal death by three times [5]. Studies have shown
perinatal mortality rates are two to three times higher
amongst babies of diabetic women as opposed to the gen-
eral population. Also higher rates of congenital anomalies
in babies of women with diabetes have been reported
compared to the general population [6,7]. Since the intro-
duction of insulin as a treatment for diabetes, mortality
and morbidity rates have improved; still, they remain sig-
nificantly higher than those of the general population.
Longer term glycaemic control in women with diabetes is
critical to satisfactory pregnancy outcome.
In order to decrease the rate of stillbirths among
maternal diabetics, a variety of interventions have been
adopted. The keystone of these interventions has been
early detection of diabetes with monitoring of blood glu-
cose levels and where needed interventions to ‘normal-
ize’ these so that complications can be reduced. The
objective of this review is to assess the impact of the
detection and control of maternal diabetes on stillbirths
using data from randomized studies, if available, or from
observational studies.
Methods
Literature search
In order to collect evidence for the effect of detection
and control of diabetes during pregnancy on stillbirths
or perinatal mortality as outcomes, we conducted a sys-
tematic search of all the literature published till July
2010. The databases searched were PubMed, Cochrane
Database of Systematic Reviews and WHO Regional
Databases. Besides, hand search of bibliographies of rele-
vant reviews was performed. Experts in the field were
contacted for further data or for unpublished trials. The
following search strategy was utilized for PubMed:
(“Diabetes Mellitus”[Mesh] OR “Diabetes Mellitus,
Type 2”[Mesh] OR “Diabetes Mellitus, Type 1”[Mesh]
OR “Glucose Intolerance”[Mesh] OR “Diabetes, Gestatio-
nal”[Mesh] OR “diabetes*” OR “gestational diabetes” OR
“glucose intolerance”) AND ("Pregnancy"[Mesh] OR
“Pregnancy Trimester, Third"[Mesh] OR “Pregnancy Tri-
mester, Second"[Mesh] OR “Pregnancy Trimester,
First”[Mesh] OR “Pregnancy Trimesters”[Mesh] OR
“pregnan*” OR “mother*” OR “maternal” OR “Mothers”[-
Mesh]) AND (“Fetal Mortality”[Mesh] OR “Stillbirth”[-
Mesh] OR “Perinatal Mortality”[Mesh] OR “Fetal
Death”[Mesh] OR “Embryo Loss”[Mesh] OR “Fetal Viabi-
lity”[Mesh] OR stillbirth* OR “fetal death*” OR “Fetal
loss” OR “perinatal mortality” OR miscarriage* OR abor-
tion* OR “baby’s death” OR “death of baby” OR “infant
death” OR “death of fetus” OR “intrauterine death*”)
For the purpose of our review, stillbirth was defined as
the expulsion of a dead fetus from the body of the
mother after 28 weeks of gestation. Perinatal mortality
was defined as stillbirths plus the deaths within the first
seven days of birth.
Inclusion/exclusion criteria
Inclusion criteria
• All studies linking screening, control and detection
of diabetes during pregnancy with stillbirth (or perinatal
mortality) were included
• The studies selected were from both developed and
developing countries.
• All studies were included irrespective of language.
For non-English articles, we primarily relied on the
abstracts but did not translate the entire article into
English.
• All studies were included in the meta-analyses irre-
spective of the methodological quality of the study.
• Studies were included in our review if they reported
on interventions for diabetic pregnancies and had data
on stillbirth or perinatal mortality as outcomes.
Exclusion criteria
• Studies were excluded if they did not report on rele-
vant outcomes i.e. stillbirth or perinatal mortality.
• Studies were excluded if they did not focus on the
selected interventions (screening/monitoring/
pharmacotherapy).
The studies were grouped according to the following
interventions: (1) impact of early detection (1st trime-
ster) strategies versus late detection (24th to 28th week
of gestation i.e. regular screening ) of gestational
diabetes mellitus (GDM) in pregnancy; (2) outpatient
versus hospital based monitoring and management; (3)
intensified management (dietary advice, increased fre-
quency of monitoring, increased clinic visits or phar-
macotherapy) versus conventional management
strategies for diabetes in pregnancy; (4) Optimal versus
suboptimal glucose control; (5) pre-conception care
versus no/conventional care (6) effectiveness of contin-
uous infused insulin versus multiple dose insulin; (7)
comparisons between different types of insulin; (8) oral
hypoglycemic agents and metformin use in diabetic
pregnancies versus insulin treatment or no treatment;
(9) Pregestational and gestational DM versus normal
pregnancy.
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Data abstraction
The data were extracted by two researchers into a stan-
dard Web excel sheet prepared by the CHERG/LiST
review group [8]. The variables considered included, for
example, location of the study, setting, study design,
blinding assessment, allocation concealment, intention-
to-treat analysis, lost to follow-up rates, intervention
and control group definitions and study limitations.
Study characteristics and quantitative data synthesis
The study designs considered were randomized, quasi-
randomized trials and observational studies. We
generated meta-analyses using RevMan 5.0 software for
outcomes where more than one study was available [9].
The assessment of statistical heterogeneity among trials
was done by visual inspection i.e. the overlap of the con-
fidence intervals among the studies, and by the Chi
square (P-value) of heterogeneity in the meta-analyses.
A low P value (less than 0.10) or a large chi-squared sta-
tistic relative to its degree of freedom was considered as
providing evidence of heterogeneity. The I2 values were
also looked into, and an I2 value greater than 50% was
taken to represent substantial and high heterogeneity. In
situations of substantial or high heterogeneity being pre-
sent, causes were explored, sub-group analyses per-
formed and random effects model was used; and
although, this random model is not a substitute for a
thorough investigation of heterogeneity, it was primarily
to take into account heterogeneity that could not be
explained.
Summary estimates were presented as relative risk
with 95% confidence interval. For cluster randomized
trials, the cluster-adjusted values were used if reported
in the studies themselves. We also applied the CHERG
adaptation of the GRADE criteria to grade the evidence
presented by the studies in our meta-analyses [8,10].
The Child Health Epidemiology Reference Group
(CHERG) guidelines are applied by scientists conducting
reviews of intervention effects for use in The Lives
Saved Tool (LiST). The six steps in the CHERG inter-
vention review process include: (i) defining the scope of
the review; (ii) conducting the literature search; (iii)
extracting information from individual studies; (iv)
assessing and summarizing the evidence; (v) translating
the evidence into estimates of intervention effects and
(vi) presenting the results.
The Lives Saved Tool (LiST) uses estimates of the
effects of interventions on cause-specific child mortality
as a basis for generating projections of child lives that
could be saved by increasing coverage of effective inter-
ventions. Estimates of intervention effects are an essen-
tial element of LiST, and need to reflect the best
available scientific evidence [8].
The World Bank list of economies (July 2009) [11]
was used to classify countries into developing and devel-
oped. Low- and middle-income countries were taken as
developing, while high income countries were taken as
developed.
Delphi process for establishing expert consensus
For the intervention of diabetes screening and manage-
ment, in general, during pregnancy, we also sought
expert consensus via the Delphi method. The Delphi
technique (subsequently referred to as the Delphi) uses
a series of sequential questionnaires or ‘rounds’, inter-
spersed by controlled feedback, that seek to gain the
most reliable consensus of opinion among a group of
experts. It is a technique that is useful for situations
where individual judgments must be tapped and com-
bined in order to address a lack of agreement or incom-
plete state of knowledge. As such, the Delphi is
particularly valued for its ability to structure and orga-
nize group communication [12]. The panel invited to
participate were experts in maternal health representing
six WHO regions (South Asia, Africa, Western Europe,
Eastern Europe, North America, Australia), and includ-
ing multiple disciplines - international health, obstetrics/
gynecology, midwifery, etc. Thirty-one experts agreed to
participate in the Delphi process. The questionnaire was
developed by MYY and ZAB, and refined after several
rounds of pilot testing. The questionnaire was sent by
email. It included the background and aims of the Del-
phi and estimates of effect that were available from the
literature for different scenarios. The median response
and range were determined for each question. Consen-
sus was defined a priori as an inter-quartile range in
responses of not more than 30% for each question. For
those estimates not reaching consensus, the plan was for
results to be electronically distributed to the panel, vir-
tual discussion allowed, and a second round of email
questionnaires sent. However, consensus was achieved
after one round of questionnaires and subsequent
rounds were not necessary.
Results
The above mentioned search strategy yielded 2162 hits
that were reviewed and 261 abstracts of interest were
preliminarily selected. After careful review of these stu-
dies, 70 studies were reviewed in detail. A flow diagram
detailing the study abstraction process is given below
(figure 1). Our search yielded 14 intervention studies
[13-25] and 56 observational studies [16,26-80]. The stu-
dies included in review articles, which were not in our
short-listed articles, were added as hand searched from
bibliography. In depth characteristics of these studies
are presented in Additional File 1.
Syed et al. BMC Public Health 2011, 11(Suppl 3):S2
http://www.biomedcentral.com/1471-2458/11/S3/S2
Page 3 of 12
(1) a. Impact of early detection strategies versus late
detection of GDM in pregnancy
A single cohort study [38] compared early testing
(before 24 weeks) versus regular schedule (i.e. glucose
challenge test/OGTT between 24th to 28th week of
gestation) of testing in a group of women with a history
of GDM in prior pregnancy. This study was unable to
show that early testing was better than late testing in
improving perinatal mortality. This is supported by a
review by Hillier et al. [81] that also did not find any
randomized trials evaluating risks or benefits of early
detection.
(1) b. Other screening strategies
Two other observational studies focused on screening of
diabetes using different criteria. The cohort study by
Schmidt et al 2001 [68] compared two sets of screening
criteria for GDM; ADA (American Diabetic Association
criteria) versus WHO criteria. There were a total of 13
deaths (7 fetal deaths and 6 early neonatal deaths) with
no difference using either set of criteria (ADA criteria:
RR 3.1,95 CI% 1.42-6.47; WHO criteria: RR 1.59, 95%
CI 0.86-2.90). A study by Ezimokhai et al 2006 [40]
compared effect of universal screening (2001-2002) ver-
sus selective screening (1996-1997) of high risk candi-
dates. No significant difference in intrauterine fetal
death was observed (RR 0.42, 95% CI 0.16 -1.12)
between either groups.
(2) Outpatient versus hospital based monitoring and
management
Two observational studies focusing on hospital based
versus outpatient monitoring were retrieved in our
search. A controlled prospective trial by Nachum et al.
[62] on pregestational and gestational diabetics com-
pared ambulatory monitoring versus repeat hospitaliza-
tions. No difference in effect on risk of perinatal
mortality or neonatal mortality was observed (RR 0.98,

Screened titles and 
abstracts 
2162 titles identified through a 
PubMed based search. 
Detailed review 
261 articles reviewed for 
eligibility. 
A total of 70 articles selected for data 
extraction after adding articles from 
hand searched bibliographies. 
Screening for 
relevant outcomes 
Ante-partum 
Stillbirths
Intrapartum 
Stillbirths 
Perinatal Mortality 
Figure 1 Synthesis of literature search in this review of the effect of detection and management of maternal diabetes mellitus on perinatal
mortality as an outcome of pregnancy.
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95% CI 0.14-6.77). A retrospective cohort study by
Traub et al.1987 [72] compared treatment in peripheral
maternity units with hospital based (centralized) treat-
ment. No difference in effect on rates of stillbirth were
noted (RR=0.42, 95% CI 0.09-2.01).
(3) Intensified management (dietary advice, monitoring or
pharmacotherapy) versus no or conventional
management strategies for diabetes in pregnancy
A number of studies have focused on the impact of
monitoring and treatment of diabetes in pregnancy ver-
sus no care/conventional care. In our review one study
[15] studied the impact of intensive monitoring versus
routine monitoring of serum glucose levels in a popula-
tion of pregnant women with impaired glucose toler-
ance. The intervention group received dietary advice,
capillary blood glucose monitoring five times a week
and HbA1c measurements monthly, wheras the routine
monitoring group received dietary advice and monthly
HbA1c measurement. No stillbirths were reported in
either comparison group. This was the only study which
assessed the effect of monitoring of glucose levels in
women with impaired glucose tolerance in pregnancy.
Four intervention studies [13,23-25] with randomized
design assessed the same comparison of intensified versus
conventional management in women with GDM. Pooling
of results from these three studies displays an 80% non-
significant reduction in risk of stillbirth (RR=0.20, 95% CI:
0.03- 1.10) when intensive management protocols are
utilized (figure 2). Of these studies, Langer et al. 1994
focused on assessing the effect of intensified monitoring
(7 checks of serum glucose/day) versus conventional mon-
itoring in a group of women with gestational diabetes.
This was coupled with treatment as dictated by serum glu-
cose levels. A non significant effect was seen on risk of
stillbirths (RR=0.23, 95% CI 0.03-1.97) and neonatal
mortality (RR=1.49, 95% CI 0.23- 5.68). A randomized
controlled trial by Crowther et al. 2005 consisting of 1031
subjects, reported a non-significant impact on the risk of
perinatal mortality (RR = 0.09; 95% CI: 0.01 – 1.70) when
gestational diabetics received individualized dietary advice,
serum glucose monitoring and insulin therapy compared
to routine care. Three stillbirths were reported in the rou-
tine care group (p-value 0.25). A similar trial by Garner et
al 1997 conducted on patients with GDM comprising a
small sample size (300 subjects) did not report any still-
births. An RCT conducted by Landon et al. 2009 [25]
focused on intensive treatment of gestational diabetes ver-
sus conventional management. It did not report any peri-
natal deaths in either groups but displayed positive effect
of intervention on risk of large for gestational age (LGA),
shoulder dystocia, need for cesarean section, gestational
hypertension and pre eclampsia. Table 1 gives the quality
grading of the outcome(s) according to the CHERG rules.
Observational studies which looked at similar compari-
sons were also identified [28,32,33,35,49,50,75]. A cohort
study by Huddle et al. (2005) [50] focused on pregesta-
tional and gestational diabetes in a population of black
Study or Subgroup
5.2.1 Randomized Controlled Trials
Crowther 2005
Garner 1997
Landon  2009
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
5.2.2 Quasi - Randomized Controlled Trials
Langer 1994
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.06, df = 1 (P = 0.81); I² = 0%
Test for overall effect: Z = 1.85 (P = 0.06)
Test for subgroup differences: Not applicable
Events
0
0
0
0
1
1
1
Total
506
150
485
1141
1145
1145
2286
Events
3
0
0
3
5
5
8
Total
524
150
473
1147
1316
1316
2463
Weight
42.5%
42.5%
57.5%
57.5%
100.0%
M-H, Fixed, 95% CI
0.15 [0.01, 2.86]
Not estimable
Not estimable
0.15 [0.01, 2.86]
0.23 [0.03, 1.96]
0.23 [0.03, 1.96]
0.20 [0.03, 1.10]
Experimental Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 2 Intensive care for gestational diabetes (dietary advice, clinical monitoring +/- treatment) versus conventional management. Outcome:
Pooled data for stillbirth.
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women. Initial hospitalization, intensive monitoring and
management in one group were compared to only two
weeks of intensive management in the group that
enrolled late. Positive effect was seen on rates of stillbirth
in patients with GDM and pregestational diabetes [Still-
birth: GDM (RR=0.23, 95%CI 0.12-0.47), type 1 diabetes
(RR=0.32, 95%CI 0.15-0.72), type 2 diabetes (RR=0.077,
95%CI 0.019-0.32)].
Three observational studies assessed women for dia-
betes during pregnancy followed by treatment for those
who tested positive. Those who were tested positive and
treated were the compared to those that tested negative.
[27,54,64] A retrospective cohort by Koukkou et al.
1995 [54] tested high risk women for GDM, followed by
comparison of outcomes between women who tested
positive with those that did not. No significant impact
on stillbirth rates was seen (RR 2.08, 95% CI 0.19-22.7).
Similar results were seen in a cohort study by Philipson
et al 1985 [64] who compared women who tested posi-
tive for GDM versus those who did not. A study by
Beischer et al compared women who tested positive for
GDM versus those that were normal. This study
screened the population for gestational diabetes and
assessed effect on perinatal mortality. The study also
gave data on difference in mild and severe gestational
diabetes. It reported a decreasing trend in stillbirth rates
between 1971 and 1994.
Applying CHERG Rules for Evidence Reviews for
LiST, we gave a ‘moderate’ level quality evidence for the
impact of intensified versus conventional management
on stillbirths [8]. The total number of events was less
than 50 (Rule 0 applies) and so there is insufficient evi-
dence to recommend this estimate for the LiST model.
One of the studies was quasi randomized [13] and
another [24] had a small sample size from which con-
clusions could not be drawn. We, therefore, use the
Delphi results to make a recommendation for the inter-
vention of diabetes screening and management.
(4) Optimal versus suboptimal glucose control
Four observational studies [26,42,61,70] focused on the
comparison of optimal control of serum glucose versus
suboptimal control. Two studies [42,70] reported data
on stillbirths and three [26,61,70] had data on perinatal
mortality. Pooled data from these studies did not display
a significant difference in risk of stillbirth (RR=0.51, 95%
CI 0.14-1.88) (figure 3). However, perinatal mortality
was significantly reduced (RR=0.40, 95% CI 0.25- 0.63)
(figure 4).
For the comparison of optimal versus suboptimal con-
trol of diabetes two cohort studies [42,70] reporting
stillbirth risk were identified. Of these only one study
[70] had adjusted for confounding factors. The outcome
of stillbirth was given ‘low’ evidence because these were
cohort studies and could not be used for recommending
into the LiST tool because the total events were less
than 50 (Rule 0 application) [8].
(5) Pre-conception care for pregestational diabetes versus
No care/conventional care
Four observational studies [29,36,71,74] focused on the
impact of preconception care (information about need
for optimization of glycemic control before pregnancy,
assessment of diabetes complications, review of dietary
habits, intensification of capillary blood glucose self-mon-
itoring and optimization of insulin therapy) versus no
preconception care in pre gestational diabetes. Two of
these studies included both type 1 and 2 diabetics [29,74]
and the other two focused on type 1 diabetes only
[36,71]. Of these 3 studies, one [74] was not adjusted for
confounding factors and one was a multicentre cross sec-
tional study; the evidence from these trials was deemed
to be of ‘moderate’ outcome specific quality. Two studies
(Temple et al.2006 [71] and Boulot et al. 2003 [29])
focused on providing intensive preconception care
including information about need for optimization of gly-
cemic control before pregnancy, assessment of diabetes
complications, review of dietary habits, intensification of
capillary blood glucose self-monitoring and optimization
of insulin therapy. One study [74] focused only on pre-
conception counseling. The study by Cyganek et al. 2010
[36] focused on pre pregnancy planning in women who
were receiving continuous subcutaneous insulin infusion
or multiple daily injections. There were 14 malforma-
tions, stillbirths, and perinatal infant deaths in the not-
planning versus five in the planning group (P = 0.07).
Table 1 Quality grading of outcomes according to the CHERG approach using adapted GRADE criteria
No of
studies
(ref)
Design Limitations Consistency Generalizability
to population
of interest
Generalizability to
intervention of
interest
Intervention Control Relative
Risk
(95% CI)
Intensified versus conventional management (Stillbirths): MODERATE outcome specific quality
4 3
RCTs,1
quasi
RCT
Small study size in 1 study, 1
study not strictly randomized
and 80% of the subjects
were Hispanic so may not be
generalizable.
2/4 studies showing
direction of benefit,
while the remaining
two had zero total
events
All in developed
countries
Cannot separate diet
controlled from diet
and insulin
controlled diabetes
during pregnancy
1 8 RR
(fixed) =
0.20
(0.03-
1.10)
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(6) The effectiveness of continuous infused insulin versus
multiple dose insulin
Seven studies focused on the comparison of continuous
subcutaneous insulin versus conventional multiple injec-
tions of insulin. Six of these studies were intervention
studies [16-21] and one was an observational study [47].
Of the six intervention studies [16-21] five were on
type 1 diabetics and one included both type 1 and 2 dia-
betics [20]. Data from one study could not be added as
the full text of the article was unavailable [17].
The single observational study retrieved for this com-
parison did not report any significant effects on perina-
tal mortality (p-value = not significant).
Data for stillbirths from the intervention studies was
pooled and the following non-significant effect was seen
(OR= 3.17, 95% CI 0.71-14.28) (figure 5).
In conclusion, three RCTs [16,20,21] and 2 quasi
RCTs [18,19] focused on the intervention of continuous
subcutaneous insulin infusion versus conventional mul-
tiple insulin injections. None reported significant results.
The meta-analysis did not reveal statistically significant
impact on stillbirth risk. Studies provided a moderate
level of evidence for showing no significant benefit of
continuous subcutaneous insulin compared to multiple
dose therapy on risk of stillbirths.
(7) Comparisons between different types of insulin
Four studies; two RCTs [14], [22] one retrospective
cohort [78] and one prospective cohort study [63] on
compared different types of insulin. Of the two rando-
mized trials, Hod et al. 2008 [14] compared the effect of
insulin aspart versus human insulin. The comparison of
Study or Subgroup
4.2.1 Cohort Study
Bannerjee 2004
Mirghani 2001
Temple 2002
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 4.08, df = 2 (P = 0.13); I² = 51%
Test for overall effect: Z = 3.93 (P < 0.0001)
Total (95% CI)
Total events
Heterogeneity: Chi² = 4.08, df = 2 (P = 0.13); I² = 51%
Test for overall effect: Z = 3.93 (P < 0.0001)
Test for subgroup differences: Not applicable
Events
16
9
2
27
27
Total
164
56
48
268
268
Events
24
5
2
31
31
Total
76
15
110
201
201
Weight
78.3%
18.8%
2.9%
100.0%
100.0%
M-H, Fixed, 95% CI
0.31 [0.17, 0.55]
0.48 [0.19, 1.23]
2.29 [0.33, 15.80]
0.40 [0.25, 0.63]
0.40 [0.25, 0.63]
Experimental Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 4 Patients with optimal control versus suboptimal control. Outcome: Pooled data for perinatal death.
Study or Subgroup
4.1.1 Cohort Study
Gonzalez-Quintero 2007
Temple 2002
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 1.56, df = 1 (P = 0.21); I² = 36%
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI)
Total events
Heterogeneity: Chi² = 1.56, df = 1 (P = 0.21); I² = 36%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
Events
1
2
3
3
Total
48
2030
2078
2078
Events
1
4
5
5
Total
110
1188
1298
1298
Weight
10.7%
89.3%
100.0%
100.0%
M-H, Fixed, 95% CI
2.29 [0.15, 35.88]
0.29 [0.05, 1.60]
0.51 [0.14, 1.88]
0.51 [0.14, 1.88]
Experimental Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 3 Patients with optimal control versus suboptimal control. Outcome: Pooled data for stillbirth.
Syed et al. BMC Public Health 2011, 11(Suppl 3):S2
http://www.biomedcentral.com/1471-2458/11/S3/S2
Page 7 of 12
insulin aspart versus human insulin on stillbirths did not
show significant effect on the risk of stillbirth (RR=1.05,
95%CI 0.07-16.7).However, there were only 322 subjects
in this trial. Persson et al. 2002 [22] studied the effects
of insulin Lispro versus regular insulin. There were no
stillbirths or neonatal deaths reported in this compari-
son. A single observational study by Aydin et al.2008
[78] assessed the comparison of insulin lispro versus
regular human insulin and did not report a significant
difference in on the risk of stillbirth (RR=2.14, 95% CI
0.14-33.03). Whereas the other prospective cohort [63]
compared the effects of glargine versus NPH insulin.
There were two stillbirths reported in the group of preg-
estational diabetics using NPH insulin and none in the
glargine utilizing group (p-value=0.028).
(8) Oral hypoglycemic agents and metformin use in
diabetic pregnancies
Five observational studies [39,46,48,51,65] focused on
the impact of using oral hypoglycemic agents or metfor-
min versus diet alone or insulin. Of these studies Holt
et al. 2008 [48] compared the effect of glibenclamide
versus insulin in a population of women with GDM. No
significant difference was seen on risk of stillbirth (RR=
3.07, 95%CI 0.13-73.31). A retrospective cohort study by
Ekpebegh et al 2007 [39]compared women treated with
oral glucose-lowering agents (OGLA-metformin and
glibenclamide) alone (group 1) and women converted
from OGLA to insulin (group 2) with women who were
treated with insulin alone and women converted from
diet to insulin (group 3). There was a significant differ-
ence in perinatal mortality rates between group the
three groups; perinatal mortality rates (per 1000 births):
125, 28 and 33 (p-value=0.003). At least one group dif-
fered significantly from another (p-value=0.003). It is
clear that the PNM rate for those on OGLA alone, 125
per 1000, was much higher than for the other two
groups. The majority of all perinatal deaths were still-
births: eight of 11 in the OGLA alone group and five of
seven in the OGLA to insulin group.
A study by Hughes et al 2006 [51] compared use of
metformin versus none in type 2 diabetics. No signifi-
cant difference was observed in perinatal loss (p-value
=0.65). Another retrospective cohort study Rayburn et al
2006 [65] compared pregnancies requiring oral hypogly-
cemic drugs with those controlled with diet alone.
A single stillbirth was reported in the diet controlled
group with none in the treatment group and the results
were not significant. Hellmuth et al. 2007 compared
metformin with sulphonylureas in pregnant diabetic
patients and a reference group treated with insulin.
(9) Pregestational and gestational DM versus normal
pregnancy
Our literature search also yielded studies which assessed
the risk of stillbirth in the above mentioned comparison.
Twelve observational studies assessing the risk of stillbirth
in pre-gestational and gestational diabetes versus normal
pregnancies [82-93] were identified. Of these, five studies
[82-86] could be pooled to assess risk of stillbirth in
women with diabetic pregnancy versus normal women.
Pooled data from these studies displayed a significant
effect on stillbirth risk in the fixed effects model (RR 2.17,
95% CI 1.45-3.25). Due to considerable heterogeneity
Study or Subgroup
1.1.1 Randomized Controlled Trials
Carta 1986
Coustan 1986
Nosari 1993
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.27, df = 1 (P = 0.60); I² = 0%
Test for overall effect: Z = 1.18 (P = 0.24)
1.1.2 Quasi Randomized Controlled Trials
Botta 1986
Burkart 1988
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.02, df = 1 (P = 0.89); I² = 0%
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.29, df = 3 (P = 0.96); I² = 0%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.97), I² = 0%
Events
2
0
2
4
1
1
2
6
Total
14
11
16
41
5
48
53
94
Events
0
0
1
1
0
0
0
1
Total
15
11
16
42
5
41
46
88
Weight
23.1%
36.0%
59.1%
19.2%
21.7%
40.9%
100.0%
IV, Fixed, 95% CI
6.20 [0.27, 141.32]
Not estimable
2.14 [0.17, 26.33]
3.25 [0.46, 22.98]
3.67 [0.12, 113.73]
2.62 [0.10, 66.10]
3.07 [0.29, 32.23]
3.17 [0.71, 14.28]
Experimental Control Odds Ratio Odds Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 5 Continuous SC insuline pump versus conventional mulitiple insuline injections. Outcome: pooled stillbirth/IUFD.
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I2=95% and p-value <0.10, a random effects model was
also applied which indicated that the results were statisti-
cally insignificant (RR=3.38, 95%CI 0.49-23.34).
Delphi results
Figure 6 summarizes the estimates (medians) from the
Delphi consensus for the effect of intervention of dia-
betes screening and management versus no specific iden-
tification or care for women with diabetes. The experts
determined the effect to be 10% reduction in antepartum
stillbirth (or intrauterine death). (interquartile range of
5% to 30%) and 10% reduction in intrapartum stillbirth
(interquartile range of 3.5% to 25%). These figures have
been recommended for use in the LiST model.
Discussion
This systematic review attempts to summarize the evi-
dence in the literature regarding the prevention and
management of gestational and pregestational diabetes
and the effect on stillbirths. We have performed meta-
analyses where possible to estimate impact of prevention
and treatment strategies on stillbirth. We found substan-
tial differences in clinical and methodological approaches
across all studies with variability in interventions, defini-
tions of outcomes, study design and risk of bias.
Although the focus was on interventions having an
impact on stillbirth risk we found that there was a lack
of data regarding this outcome in most studies. Some
studies included present stillbirths as part of perinatal
mortality. With regard to screening strategies no rando-
mized controlled trial has been reported that directly
evaluates the risks and benefits of early diabetes screen-
ing [81]. Our systematic review identified 4 studies
focusing on intensive treatment of diabetes versus con-
ventional management. A reduction of 80% was
observed in stillbirth risk with intensive management
but was not statistically significant. A systematic review
by Alwan et al. 2009 [4] focusing on treatment of gesta-
tional diabetes reported positive benefits on maternal
preeclampsia (five trials, 1255 women; RR = 0.95, 95%
CI 0.80 to 1.12) and macrosomia when any specific
treatment is utilized versus routine antenatal care for
GDM, however, results were not significant. A recent
review by Horvath et al. 2010 [94] focusing on the same
comparison reported similar effects on risk of macroso-
mia, shoulder dystocia and preeclampsia.
For the comparison of optimal versus suboptimal control
of diabetes two cohort studies [42,70] reporting stillbirth
risk were identified. Three studies [26,61,70] reported peri-
natal mortality for the same comparison; and a 60% reduc-
tion in risk of perinatal mortality was seen in women with
optimal glucose control, which was statistically significant.
A similar comparison was performed by Inkster and collea-
gues 2006 [5]. Similar findings were reported in their
review regarding perinatal mortality. Increased perinatal
mortality was associated with poor glycaemic control,
pooled odds ratio 3.03 (95% CI: 1.87 to 4.92).
For the intervention of continuous subcutaneous insulin
infusion versus conventional multiple insulin injections a
systematic review by Mukhopadhay et al. 2007 [95] was
identified. This review also reported that no significant dif-
ference in glycemic controls or pregnancy outcomes
including stillbirths was seen when the two different treat-
ment strategies (continuous subcutaneous insulin versus
conventional daily injections) were compared. It is noted
that studies included in the pooled analyses had small
sample sizes and further studies with larger sample sizes
may be needed for more conclusive results [95].
In the treatment of diabetes during pregnancy the spot-
light is often on insulin therapy; however, in recent years
studies have been done that assess the impact of oral
hypoglycemic agents and metformin on pregnancy out-
comes. A recent systematic review concluded that no sig-
nificant differences were found in maternal glycemic
control or cesarean delivery rates between the insulin and
glyburide groups. There was a higher proportion of infants
with neonatal hypoglycemia in the insulin group (8.1%)
compared with the metformin group (3.3%) (P-value:
0.008). Also the rate of congenital malformations, which
contribute to stillbirth risk, did not differ between preg-
nancies treated with insulin and those treated with oral
agents [96]. Another systematic review [4] reported a 54%
reduction in the rates of cesarean section in women who
received oral hypoglycemic therapy compared to insulin.
Currently, data are insufficient to conclude that the use of
oral hypoglycemic agents reduces the risk of stillbirth in
women who have GDM.
Diabetes in pregnancy is also associated with higher
rates of miscarriage, pre-eclampsia, preterm labour and
higher rates of fetal malformation [97]; neural tube defect,
Figure 6 Box plots for the Delphi results on diabetes screening and
management during pregnancy.
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urinary tract disorder, macrosomia, birth injury, and peri-
natal mortality. These risks can be minimized by optimal
glycaemic control, both prior to and throughout the preg-
nancy [98,99], and this is best achieved through compre-
hensive preconception care where other issues such as
genetic risks, health status, reproductive history, exposure
to environment toxins, immunization and life-style risk
factors can be addressed via a community based approach
to manage diabetes before and during pregnancy [100].
Conclusions
Diabetes, and especially pregestational diabetes with its
attendant vascular complications, is clearly a significant
risk factor for stillbirth. Our review highlights the fact that
very few studies of adequate quality are available that can
provide data on the impact of screening and management
of diabetes in pregnancy and stillbirth risk. Applying the
CHERG rules, we deduced a 62% reduction in stillbirths
due to intensive vs. conventional management of gesta-
tional diabetes. The Delphi process however, suggested a
more conservative figure of 10% reduction in the risk of
antepartum and intraprtum stillbirths and presently these
point estimates are being recommended for use in LiST.
Additional material
Additional file 1: This paper has an additional file that contains all
of the studies that were graded for quality for inclusion in the
analyses. This file is a word document.
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